- Home
- IMUX vs APLT Comparison
IMUX vs APLT Comparison
Compare IMUX & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- APLT
- Stock Information
- Founded
- IMUX 2016
- APLT 2016
- Country
- IMUX United States
- APLT United States
- Employees
- IMUX N/A
- APLT N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- IMUX Health Care
- APLT Health Care
- Exchange
- IMUX Nasdaq
- APLT Nasdaq
- Market Cap
- IMUX 102.2M
- APLT 80.3M
- IPO Year
- IMUX N/A
- APLT 2019
- Fundamental
- Price
- IMUX $1.12
- APLT $0.50
- Analyst Decision
- IMUX Strong Buy
- APLT Buy
- Analyst Count
- IMUX 6
- APLT 7
- Target Price
- IMUX $12.67
- APLT $6.10
- AVG Volume (30 Days)
- IMUX 904.4K
- APLT 2.6M
- Earning Date
- IMUX 05-07-2025
- APLT 05-08-2025
- Dividend Yield
- IMUX N/A
- APLT N/A
- EPS Growth
- IMUX N/A
- APLT N/A
- EPS
- IMUX N/A
- APLT N/A
- Revenue
- IMUX N/A
- APLT N/A
- Revenue This Year
- IMUX N/A
- APLT N/A
- Revenue Next Year
- IMUX N/A
- APLT $2,426.33
- P/E Ratio
- IMUX N/A
- APLT N/A
- Revenue Growth
- IMUX N/A
- APLT N/A
- 52 Week Low
- IMUX $0.92
- APLT $0.43
- 52 Week High
- IMUX $2.11
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- IMUX 51.41
- APLT 38.29
- Support Level
- IMUX $1.06
- APLT $0.49
- Resistance Level
- IMUX $1.22
- APLT $0.61
- Average True Range (ATR)
- IMUX 0.09
- APLT 0.06
- MACD
- IMUX -0.01
- APLT 0.03
- Stochastic Oscillator
- IMUX 37.50
- APLT 37.68
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.